MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Purchased by American Century Companies Inc.

American Century Companies Inc. boosted its position in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 42.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,008 shares of the company’s stock after buying an additional 11,907 shares during the quarter. American Century Companies Inc. owned approximately 0.06% of MeiraGTx worth $168,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its position in shares of MeiraGTx by 1.9% during the 1st quarter. Russell Investments Group Ltd. now owns 157,999 shares of the company’s stock valued at $959,000 after acquiring an additional 2,994 shares during the period. Acadian Asset Management LLC purchased a new position in MeiraGTx during the first quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. boosted its position in MeiraGTx by 66.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 12,246 shares of the company’s stock worth $74,000 after purchasing an additional 4,892 shares in the last quarter. Rhumbline Advisers grew its holdings in MeiraGTx by 10.8% in the second quarter. Rhumbline Advisers now owns 52,996 shares of the company’s stock valued at $223,000 after purchasing an additional 5,178 shares during the period. Finally, Tocqueville Asset Management L.P. increased its position in shares of MeiraGTx by 16.3% in the first quarter. Tocqueville Asset Management L.P. now owns 39,500 shares of the company’s stock valued at $240,000 after buying an additional 5,550 shares in the last quarter. Hedge funds and other institutional investors own 67.48% of the company’s stock.

MeiraGTx Stock Performance

NASDAQ MGTX opened at $4.15 on Friday. The company has a debt-to-equity ratio of 1.04, a current ratio of 2.36 and a quick ratio of 2.36. The stock’s 50 day simple moving average is $4.26 and its 200-day simple moving average is $4.77. The company has a market cap of $266.87 million, a PE ratio of -3.55 and a beta of 1.28. MeiraGTx Holdings plc has a 1-year low of $3.49 and a 1-year high of $7.60.

MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.45). MeiraGTx had a negative net margin of 1,146.81% and a negative return on equity of 152.82%. The firm had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $16.38 million. As a group, equities research analysts anticipate that MeiraGTx Holdings plc will post -1.37 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Perceptive Advisors Llc purchased 1,250,000 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average price of $4.00 per share, with a total value of $5,000,000.00. Following the completion of the acquisition, the director now owns 12,531,103 shares in the company, valued at $50,124,412. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 8.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on MGTX. Royal Bank of Canada dropped their price target on shares of MeiraGTx from $11.00 to $9.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Chardan Capital reiterated a “buy” rating and issued a $36.00 target price on shares of MeiraGTx in a research report on Wednesday, July 31st.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.